Legal Representation
Attorney
Scott D. Woldow
USPTO Deadlines
Next Deadline
1401 days remaining
Section 8 Declaration Due (Principal Register) (Based on registration date 20231024)
Due Date
October 24, 2029
Grace Period Ends
April 24, 2030
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
20 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Oct 24, 2023 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Oct 24, 2023 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Aug 8, 2023 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Aug 8, 2023 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Jul 19, 2023 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jun 30, 2023 | FIXD | O | ELECTRONIC RECORD REVIEW COMPLETE | Loading... |
| Jun 23, 2023 | ERRR | O | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED | Loading... |
| Jun 16, 2023 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jun 14, 2023 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jun 13, 2023 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jun 13, 2023 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| May 24, 2023 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| May 24, 2023 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| May 24, 2023 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| May 17, 2023 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jan 27, 2023 | AMPX | O | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | Loading... |
| Jan 27, 2023 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Nov 29, 2022 | PARI | I | TEAS VOLUNTARY AMENDMENT RECEIVED | Loading... |
| Nov 8, 2022 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Nov 8, 2022 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations for human use for the treatment of neurological diseases and disorders, immunological diseases and disorders, inflammatory diseases and disorders, oncological diseases and disorders and viral infections
Classification
International Classes
005